Literature DB >> 15246157

A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells.

Hideki Harada1, Satoru Watanabe, Kaoru Saijo, Isamu Ishiwata, Tadao Ohno.   

Abstract

OBJECTIVE: A Wilms tumor cell line, HFWT, selectively stimulates expansion of natural killer (NK) cells from human peripheral blood mononuclear cells (PBMC). In this study, we attempted to identify NK precursors in PBMC or in cord blood mononuclear cells (CBMC) that preferentially respond to feeder HFWT cells.
MATERIALS AND METHODS: Human NK cells or candidate precursor cells were fractionated from PBMC or CBMC by magnetic antibody cell sorting or by flow cytometry and applied to limiting dilution analysis to determine the proportion of NK/NK precursor cells, which are able to proliferate on irradiated HFWT cells. NK and NK precursor cells were cultured in medium containing interleukin-2 (IL-2). Expansion of NK cells from both resting NK cells and NK precursor cells was examined using proliferation from single cells, expression of NK cell markers, and cytotoxic activity.
RESULTS: In the limiting dilution analysis, NK cells expanded on irradiated HFWT cells not only from CD3-CD56bright and CD3-CD56dim NK cells, but also from CD16+/-CD122+ cells in the lineage-negative (Lin-, CD3-CD14-CD19-CD56-) cell fraction. The feeder HFWT cells stimulated Lin-CD122+ cell proliferation more strongly than feeder cells from the well-known human NK target cell line K562. CBMC contained significantly higher percentages of Lin-CD122+ cells than PBMC.
CONCLUSION: CD3-CD14-CD19-CD56- cells expressing CD122+ (a subunit of the IL-2 receptor) preferentially respond to HFWT feeder cells and are novel precursors of CD3-CD56+ NK cells in human PBMC and CBMC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246157     DOI: 10.1016/j.exphem.2004.03.011

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  12 in total

1.  Natural killer cell engineering for cellular therapy of cancer.

Authors:  D R Shook; D Campana
Journal:  Tissue Antigens       Date:  2011-12

Review 2.  NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?

Authors:  Catharina H M J Van Elssen; Stefan O Ciurea
Journal:  Int J Hematol       Date:  2017-12-01       Impact factor: 2.490

Review 3.  Bringing natural killer cells to the clinic: ex vivo manipulation.

Authors:  Richard W Childs; Maria Berg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

4.  Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells.

Authors:  Bartosz Grzywacz; Nandini Kataria; Magdalena Sikora; Robert A Oostendorp; Elaine A Dzierzak; Bruce R Blazar; Jeffrey S Miller; Michael R Verneris
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

5.  Gene Transduction of Natural Killer Cells for Clinical Application.

Authors:  Noriko Shimasaki
Journal:  Methods Mol Biol       Date:  2022

Review 6.  The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells.

Authors:  Michael R Verneris; Jeffrey S Miller
Journal:  Br J Haematol       Date:  2009-10       Impact factor: 6.998

Review 7.  Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.

Authors:  Markus Granzin; Juliane Wagner; Ulrike Köhl; Adelheid Cerwenka; Volker Huppert; Evelyn Ullrich
Journal:  Front Immunol       Date:  2017-04-26       Impact factor: 7.561

Review 8.  Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.

Authors:  Margaret G Lamb; Hemalatha G Rangarajan; Brian P Tullius; Dean A Lee
Journal:  Stem Cell Res Ther       Date:  2021-03-25       Impact factor: 6.832

Review 9.  Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives.

Authors:  Stanislaw Schmidt; Lars Tramsen; Bushra Rais; Evelyn Ullrich; Thomas Lehrnbecher
Journal:  Oncotarget       Date:  2018-04-17

Review 10.  CAR-NK cells: A promising cellular immunotherapy for cancer.

Authors:  Guozhu Xie; Han Dong; Yong Liang; James Dongjoo Ham; Romee Rizwan; Jianzhu Chen
Journal:  EBioMedicine       Date:  2020-08-24       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.